Effect of insulin-like growth factor-I treatment on serum androgens and testicular and penile size in males with Laron syndrome (primary growth hormone resistance)

Endocrine and Diabetes Research Unit, Schneider Children's Medical Center, and Sackler School of Medicine, Tel Aviv University, Israel.

Serum gonadotrophins. androgens, insulin and insulin-like growth factor-I (IGF-I) were determined before and during long-term treatment with recombinant IGF-I of seven males with Laron syndrome, and the changes correlated with changes in testicular volume and penile size. The subjects were four boys below the age of 5, two boys aged 10 and 14 but prepubertal and one 28-year-old fully sexually developed adult. IGF-I was administered by a once daily subcutaneous injection of 150 microg/kg per day to the boys and 120 microg/kg per day to the adult patient. In the very young boys no change in serum gonadotrophins, androgens, gonads or genitals was registered. In the two older boys and the adult patient, there was a progressive rise in luteinizing hormone, follicle-stimulating hormone and testosterone. Concomitantly, there was an increase in size of the testes and penile length. The two boys started puberty. As very high serum IGF-I levels were registered in the adult patient, the daily dose was progressively decreased to 70 microg/kg per day. Stopping the IGF-I administration in this patient, according to the protocol, led to a return to pretreatment serum levels and testicular and penile size. This report shows for the first time a direct effect of IGF-I on sex hormones and sex organs in the male.

This article has been cited by other articles:

				C. Mau Kai, K. M. Main, A. Nyboe Andersen, A. Loft, M. Chellakooty, N. E. Skakkebaek, and A. Juul Serum Insulin-Like Growth Factor-I (IGF-I) and Growth in Children Born after Assisted Reproduction J. Clin. Endocrinol. Metab., November 1, 2006; 91(11): 4352 - 4360. [Abstract] [Full Text] [PDF]

				J. D. Veldhuis, J. N. Roemmich, E. J. Richmond, and C. Y. Bowers Somatotropic and Gonadotropic Axes Linkages in Infancy, Childhood, and the Puberty-Adult Transition Endocr. Rev., April 1, 2006; 27(2): 101 - 140. [Abstract] [Full Text] [PDF]

				V. Chandrashekar, D. Zaczek, and A. Bartke The Consequences of Altered Somatotropic System on Reproduction Biol Reprod, July 1, 2004; 71(1): 17 - 27. [Abstract] [Full Text] [PDF]

				Z. Laron Laron Syndrome (Primary Growth Hormone Resistance or Insensitivity): The Personal Experience 1958-2003 J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1031 - 1044. [Abstract] [Full Text] [PDF]

				K. H. Burns and M. M. Matzuk Minireview: Genetic Models for the Study of Gonadotropin Actions Endocrinology, August 1, 2002; 143(8): 2823 - 2835. [Abstract] [Full Text] [PDF]

				P. F. Backeljauw and L. E. Underwood Therapy for 6.5-7.5 Years with Recombinant Insulin-Like Growth Factor I in Children with Growth Hormone Insensitivity Syndrome: A Clinical Research Center Study J. Clin. Endocrinol. Metab., April 1, 2001; 86(4): 1504 - 1510. [Abstract] [Full Text]

				The Essential Role of IGF-I: Lessons from the Long-Term Study and Treatment of Children and Adults with Laron Syndrome J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4397 - 4404. [Abstract] [Full Text]